Guillem Genové
YOU?
Author Swipe
View article: A comprehensive molecular atlas of the mesenchymal cell types in the mouse liver
A comprehensive molecular atlas of the mesenchymal cell types in the mouse liver Open
View article: Adipose stem cells are sexually dimorphic cells with dual roles as preadipocytes and resident fibroblasts
Adipose stem cells are sexually dimorphic cells with dual roles as preadipocytes and resident fibroblasts Open
View article: Supplemental Table S1 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Table S1 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
The 57 genes of the MV score and their correlation to the microvessel density score (MVD) in the Uppsala dataset (N=180)
View article: Supplemental Table S3 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Table S3 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Multivariable analysis of prognostic markers in endocrine-treated patients
View article: Supplemental Figure S1. MV score ROC cutoffs and Kaplan-Meier survival curves for distant metastasis-free survival, split by treatment subgroups from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Figure S1. MV score ROC cutoffs and Kaplan-Meier survival curves for distant metastasis-free survival, split by treatment subgroups from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
(A) ROC and (B) Kaplan-Meier analysis of our training dataset in patient subgroups (i) All, (ii) Untreated, (iii) Untreated ER positive and (iv) Endocrine treated patients.
View article: Supplemental Table S3 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Table S3 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Multivariable analysis of prognostic markers in endocrine-treated patients
View article: Supplemental Table S5 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Table S5 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Change in MV score (14 days - baseline) vs. RECIST response
View article: Supplemental Table S5 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Table S5 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Change in MV score (14 days - baseline) vs. RECIST response
View article: Supplemental Table S2 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Table S2 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Univariable hazard ratios for distant metastasis-free survival per 25 increment increase in MV score in patient subsets of four independent datasets
View article: Data from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Data from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Purpose: The ability of vascular genes to provide treatment predictive information in breast cancer patients remains unclear. As such, we assessed the expression of genes representative of normal endothelial microvasculature (MV) in…
View article: Supplemental Table S2 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Table S2 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Univariable hazard ratios for distant metastasis-free survival per 25 increment increase in MV score in patient subsets of four independent datasets
View article: Supplemental Figure S2. Concordance index of the PAM50 and GGI signatures in combination with the MV score in four datasets from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Figure S2. Concordance index of the PAM50 and GGI signatures in combination with the MV score in four datasets from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
The concordance index of the PAM50 and GGI signatures alone or in combination with the MV score in four independent datasets
View article: Data from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Data from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Purpose: The ability of vascular genes to provide treatment predictive information in breast cancer patients remains unclear. As such, we assessed the expression of genes representative of normal endothelial microvasculature (MV) in…
View article: Supplemental Figure S3. Correlogram of the MV score and 22 gene modules in four datasets from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Figure S3. Correlogram of the MV score and 22 gene modules in four datasets from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Correlations between the MV score and 22 gene modules in (A) Uppsala dataset, (B) Stockholm dataset, (C) NKI dataset and (D) Rotterdam dataset.
View article: Supplemental Figure S3. Correlogram of the MV score and 22 gene modules in four datasets from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Figure S3. Correlogram of the MV score and 22 gene modules in four datasets from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Correlations between the MV score and 22 gene modules in (A) Uppsala dataset, (B) Stockholm dataset, (C) NKI dataset and (D) Rotterdam dataset.
View article: Supplemental Figure S2. Concordance index of the PAM50 and GGI signatures in combination with the MV score in four datasets from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Figure S2. Concordance index of the PAM50 and GGI signatures in combination with the MV score in four datasets from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
The concordance index of the PAM50 and GGI signatures alone or in combination with the MV score in four independent datasets
View article: Supplemental Table S4 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Table S4 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Multivariate evaluation of prognostic markers in endocrine-treated patients characterized by low genomic grade
View article: Supplemental Table S4 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Table S4 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
Multivariate evaluation of prognostic markers in endocrine-treated patients characterized by low genomic grade
View article: Supplemental Table S1 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Table S1 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
The 57 genes of the MV score and their correlation to the microvessel density score (MVD) in the Uppsala dataset (N=180)
View article: Supplemental Figure S1. MV score ROC cutoffs and Kaplan-Meier survival curves for distant metastasis-free survival, split by treatment subgroups from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Supplemental Figure S1. MV score ROC cutoffs and Kaplan-Meier survival curves for distant metastasis-free survival, split by treatment subgroups from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors Open
(A) ROC and (B) Kaplan-Meier analysis of our training dataset in patient subgroups (i) All, (ii) Untreated, (iii) Untreated ER positive and (iv) Endocrine treated patients.
View article: Data from The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade
Data from The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade Open
Recent progress with therapies targeting endothelial cells has drawn attention also to the pericytes as potential target cells for antiangiogenic therapy. Published data suggest that pericytes might confer resistance to vascular endothelia…
View article: Supplementary Figure 1 from The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade
Supplementary Figure 1 from The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade Open
Supplementary Figure 1 from The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade
View article: Supplementary Figure 1 from The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade
Supplementary Figure 1 from The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade Open
Supplementary Figure 1 from The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade
View article: Data from The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade
Data from The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade Open
Recent progress with therapies targeting endothelial cells has drawn attention also to the pericytes as potential target cells for antiangiogenic therapy. Published data suggest that pericytes might confer resistance to vascular endothelia…
View article: A single-cell transcriptomic inventory of murine smooth muscle cells
A single-cell transcriptomic inventory of murine smooth muscle cells Open
Smooth muscle cells (SMCs) execute important physiological functions in numerous vital organ systems, including the vascular, gastrointestinal, respiratory, and urogenital tracts. SMC differ morphologically and functionally at these differ…
View article: The SARS-CoV-2 receptor ACE2 is expressed in mouse pericytes but not endothelial cells: Implications for COVID-19 vascular research
The SARS-CoV-2 receptor ACE2 is expressed in mouse pericytes but not endothelial cells: Implications for COVID-19 vascular research Open
Humanized mouse models and mouse-adapted SARS-CoV-2 virus are increasingly used to study COVID-19 pathogenesis, so it is important to learn where the SARS-CoV-2 receptor ACE2 is expressed. Here we mapped ACE2 expression during mouse postna…
View article: RGS5 Determines Neutrophil Migration in the Acute Inflammatory Phase of Bleomycin-Induced Lung Injury
RGS5 Determines Neutrophil Migration in the Acute Inflammatory Phase of Bleomycin-Induced Lung Injury Open
The regulator of G protein signaling (RGS) represents a widespread system of controllers of cellular responses. The activities of the R4 subfamily of RGSs have been elucidated in allergic pulmonary diseases. However, the R4 signaling in ot…
View article: Retinoic acid receptor responder1 promotes development of glomerular diseases via the Nuclear Factor-κB signaling pathway
Retinoic acid receptor responder1 promotes development of glomerular diseases via the Nuclear Factor-κB signaling pathway Open
Inflammatory pathways are activated in most glomerular diseases but molecular mechanisms driving them in kidney tissue are poorly known. We identified retinoic acid receptor responder 1 (Rarres1) as a highly podocyte-enriched protein in he…
View article: Publisher Correction: Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination
Publisher Correction: Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination Open
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
View article: Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination
Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination Open